Harvard Bioscience (NASDAQ:HBIO) Announces Earnings Results

Harvard Bioscience (NASDAQ:HBIO) issued its quarterly earnings results on Monday. The medical instruments supplier reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02, Zacks reports. Harvard Bioscience had a negative net margin of 14.57% and a negative return on equity of 4.64%. Harvard Bioscience updated its Q2 2025 guidance to EPS.

Harvard Bioscience Stock Up 5.1%

Shares of Harvard Bioscience stock opened at $0.32 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. Harvard Bioscience has a 52-week low of $0.29 and a 52-week high of $3.60. The stock has a market capitalization of $14.15 million, a price-to-earnings ratio of -0.97 and a beta of 1.44. The company’s 50 day moving average price is $0.50 and its 200-day moving average price is $1.43.

Wall Street Analyst Weigh In

A number of brokerages have commented on HBIO. StockNews.com began coverage on shares of Harvard Bioscience in a research report on Tuesday, May 6th. They set a “hold” rating on the stock. Benchmark reduced their price target on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research report on Monday, March 24th. Finally, KeyCorp restated a “sector weight” rating on shares of Harvard Bioscience in a report on Wednesday, April 9th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Harvard Bioscience stock. Bank of America Corp DE increased its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 44.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,883 shares of the medical instruments supplier’s stock after acquiring an additional 11,948 shares during the quarter. Bank of America Corp DE owned about 0.09% of Harvard Bioscience worth $82,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.